Arbutus files international LNP patent suits against Pfizer and BioNTech
Arbutus Biopharma and its exclusive licensee Genevant Sciences have filed three international patent infringement lawsuits against Pfizer and BioNTech, targeting the companies' use of lipid nanoparticle (LNP) technology in their mRNA-based COVID-19 vaccines. The actions, filed on 16 July 2026, seek permanent injunctions and monetary damages across Canada and nineteen European jurisdictions covered by the Unified Patent Court (UPC).
The Canadian action, filed in the Federal Court of Canada, asserts Canadian Patent No. 2,721,333. The two UPC proceedings assert EP 4 241 767 and EP 4 495 237 respectively, and seek relief in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, and Sweden. These international cases build on an existing US action in the District of New Jersey, where Arbutus and Genevant are pursuing infringement claims over five US patents covering LNP manufacture and commercialisation.
Moderna settlement funds shareholder return
Separately, Arbutus confirmed receipt on 8 July 2026 of approximately $178 million from Moderna, representing its share of the noncontingent payment under a settlement reached in March 2026 that resolved all global patent litigation between the parties over Moderna's COVID-19 vaccines. The payment also covers Arbutus's litigation costs under its licence agreement with Genevant. Arbutus additionally expects to receive a dividend from Genevant's parent company in Q3 2026, reflecting its roughly 16% equity stake in Genevant's parent.
The company said it intends to return up to approximately $230 million to shareholders, commencing in Q3 2026, through a combination of share repurchases that may include a Dutch Auction tender offer, open market purchases, accelerated share repurchase programmes, or privately negotiated transactions. The precise form of any buyback remains subject to board approval, and Arbutus cautioned that no repurchase will commence before receipt of the expected Genevant dividend.
Market and regulatory context
The LNP patent estate has become one of the more closely watched areas of life-sciences intellectual property since the mass deployment of mRNA vaccines during the COVID-19 pandemic. Arbutus originally developed its LNP platform for RNA delivery in infectious disease and hepatitis B applications, and the technology subsequently found wide use in the mRNA vaccine space, where Moderna and the Pfizer/BioNTech partnership together administered billions of doses globally.
The UPC, which began accepting cases in June 2023, provides patentees with a single forum to pursue infringement claims across participating EU member states, a mechanism that substantially reduces the cost and complexity of multi-jurisdictional European enforcement. For Arbutus and Genevant, the UPC route represents a more efficient path to relief than the country-by-country litigation that was previously the standard approach.
Beyond the Pfizer/BioNTech and Moderna matters, Arbutus's core clinical pipeline centres on imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101), both in development for chronic hepatitis B. The company will need to demonstrate progress on those programmes to support a long-term equity story once the litigation-driven cash returns are absorbed. Investors will be watching for clarity on the timing and final quantum of the Genevant dividend, as well as the structure of the shareholder return mechanism, in the coming weeks.